유럽 ​​증후군 멀티플렉스 진단 시장 – 2030년까지의 산업 동향 및 예측

유럽 ​​증후군 멀티플렉스 진단 시장 분석 및 규모

2021년 9월에 업데이트된 세계보건기구(WHO) 보고서에 따르면 전 세계적으로 5,500만 명 이상이 치매를 앓고 있으며 매년 약 1,000만 건의 새로운 사례가 진단되고 있으며, 알츠하이머병(AD)이 대부분의 사례를 차지합니다. 이러한 희귀 질환을 감지하기 위해 여러 개의 멀티플렉스 패널이 개발되었습니다. 예를 들어, 2021년 4월 기사 "CDK 유전자를 표적으로 하는 알츠하이머병 진단을 위한 멀티플렉스 PCR의 발전"은 이 연구의 연구자들이 AD 바이오마커를 빠르고 정확하게 감지하는 것을 보여준 멀티플렉스-PCR(중합효소 연쇄 반응) 기반 진단 방법을 개발했다고 언급했습니다. 이러한 발전과 연구는 증후군 멀티플렉스 진단에 대한 수요를 증가시켜 시장을 앞으로 나아가게 합니다.

Data Bridge Market Research는 2022년에 38억 7,999만 달러였던 증후군 멀티플렉스 진단 시장이 2030년까지 7,562,530만 달러에 도달할 것으로 분석했으며, 2023년부터 2030년까지의 예측 기간 동안 연평균 성장률은 8.7%에 이를 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

유럽 ​​증후군 멀티플렉스 진단 시장 범위 및 세분화  

Market Definition

Syndromic multiplex diagnostic testing is a type of advanced diagnostic test used to detect infectious diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among others. The syndromic multiplex diagnostic also aids clinicians and hospitals in detecting the symptoms and signs of various diseases. This allows health care providers to provide the best treatment for their patients while also providing more precise outcomes and care that can be delivered more quickly.

Europe Syndromic Multiplex Diagnostic Market Dynamics

Drivers

• The rising demand for the diagnostic procedure for infectious diseases

Most patients' first symptoms of an infectious disease are not specific to the source of infection: fever, diarrhoea, coughing, headache, and so on. Traditionally, identifying the responsible disease agents involved testing for the most likely cause of a disease, waiting for test results, and then repeating the process if the results were negative.

As a result, the syndromic approach, which uses a single test for all microorganisms suspected of causing infectious disease, offers a novel approach to the problem of infectious disease diagnosis. When a disease is diagnosed, time is saved and the patient can begin treatment sooner. The syndromic multiplex diagnostic test provides more accurate, realistic, and comprehensive results in critical care. For instance, the BIOFIRE FILMARRAY technology, uses a single test to detect bacteria, viruses, fungi, or parasites that can cause infectious disease, with results available in 45 to 65 minutes.

• Rising demand for precise and timely results

Globally, there is an increasing demand for precise and timely results. For instance, Hologic, will launch the Novodiag System in Europe in October 2021. Novodiag is a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. QuantuMDx will also launch its Q-POC, a rapid PCR point-of-care diagnostic system, in July 2021. QuantuMDx's Q-POC system and its first test, a SARS-CoV-2 detection assay, have also received CE-IVD marking under the In Vitro Diagnostics Directive, allowing them to be used in Europe. Such developments are expected to fuel market growth.

• Rising diagnostic healthcare expenditure

Rising healthcare spending is expected to increase service availability and affordability, allowing patients to select better and more precise diagnostic services to manage their diseases. Increased healthcare spending makes diagnostic services more readily available. As a result, high health-care spending is a positive factor driving the syndromic multiplex diagnostic market's growth.

Opportunities

• Strategic Initiatives are taken by market players

BioMérieux received CE marking for its molecular biology ARGENE test for the multiplex detection of influenza viruses A and B, SARS-CoV-2, and RSV and hMPV viruses in December 2020. This marking has aided the company in commercializing its product, increasing revenue while also providing an opportunity for market growth.

Restraints/Challenges

• High cost of Diagnostic Products

The real-time polymerase chain reaction (PCR) is used in multiplex syndromic testing applications to deliver results with amplification curves and correct values. The syndromic multiplex diagnostic instruments have high maintenance costs. As a result, the market faces a challenge due to the high cost of instruments.

This syndromic multiplex diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the syndromic multiplex diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Cepheid (a Danaher subsidiary) received a CE mark for Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular test for detecting viruses causing COVID-19, Flu A, FluB, and respiratory syncytial virus infections. This has aided the company in expanding its presence.
• In 2020, BD announced that they had received Emergency Use Authorization (EUA) approval from the US Food and Drug Administration (FDA) for their additional molecular diagnostic test for COVID-19. The new test was also CE marked for the IVD Directive (98/79/EC). Following this announcement, the company's market credibility has increased.

Global Syndromic Multiplex Diagnostic Market Scope

The syndromic multiplex diagnostic market is segmented on the basis of product and services, infection type, disease, panels type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

• Reagents and Consumables
• Instruments, Software and Accessories
• Services

Infection Type

• Viral
• Bacterial
• Parasites
• Fungal

Disease

• Respiratory Infection
• Gastroneteritis
• Sexually Transmitted Infections
• Sepsis
• Meningitis
• Others

Panels Type

• Respiratory Panel
• GI-Enteric Panel
• Sexually Transmitted Disease Panel
• Blood-Sepsis Panel
• Meningitis Panel
• Others

End User

• Hospitals
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies
• Research Institutes
• Others

Syndromic Multiplex Diagnostic Market Regional Analysis/Insights

The syndromic multiplex diagnostic market is analyzed and market size insights and trends are provided by country, product and services, infection type, disease, panels type and end user as referenced above.

The countries covered in the syndromic multiplex diagnostic market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

Germany syndromic multiplex diagnostic market is expected to grow due to an upsurge in the prevalence of infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The syndromic multiplex diagnostic market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for syndromic multiplex diagnostic market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the syndromic multiplex diagnostic market. The data is available for historic period 2011-2021.

Competitive Landscape and Syndromic Multiplex Diagnostic Market Share Analysis

The syndromic multiplex diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to syndromic multiplex diagnostic market.

Some of the major players operating in the syndromic multiplex diagnostic market are:

• Seegene Inc. (South Korea)
• Luminex Corporation (U.S.)
• F. 호프만-라 로슈 유한회사(스위스)
• BD(미국)
• Bio-Rad Laboratories, Inc. (미국)
• 다나허(미국)
• QIAGEN(독일)
• 애벗(미국)
• 홀로직 주식회사(미국)
• Thermo Fisher Scientific Inc. (미국)
• 지멘스 헬스케어 GmbH(독일)
• Biocartis(벨기에)
• QuantuMDx 그룹 유한회사(영국)
• Bosch Healthcare Solutions GmbH(독일)
• 프로미넥스 주식회사(미국)
• 쿠레티스(독일)

SKU-56030